Foresee Pharmaceuticals Co., Ltd. is a Taiwan-based company mainly engaged in the research and development of new pharmaceuticals. The Company's main products include prostate cancer treatment product FP-001 and asthmatic/chronic obstructive pulmonary disease treatment product FP-025. It also engages in new pharmaceuticals clinic trial business.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
26-10-28	NT$76.50	+1.73%	23,317
26-10-27	NT$75.20	-1.05%	46,267
26-10-22	NT$76.00	-0.65%	110,068
26-10-21	NT$76.50	-0.78%	75,232
26-10-20	NT$77.10	-0.39%	75,009

End-of-day quote Taipei Exchange

More quotes

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

76.50TWD

Average target price

153.00TWD

Spread / Average Target

+100.00%

Consensus

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Foresee Pharmaceuticals Co., Ltd.

Company calendar

End-of-day quote Taipei Exchange 2026-10-28			5-day change	1st Jan Change
76.50 ^TWD	+1.73%		-0.78%	-5.09%

10-12	Foresee Pharmaceuticals Co., Ltd. and Changchun GeneScience Pharmaceutical Co., Ltd. Receive China NMPA Approval of CAMCEVI 42 Mg for Treatment of Advanced Prostate Cancer	CI
08-14	Foresee Pharmaceuticals Co., Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI

Market Cap	12.05B 372M 333M 307M 279M 520M 35.42B 528M 3.68B 1.47B 18.55B 1.4B 1.37B 58.69B	P/E 2024	-9.84x	P/E 2025	-14.1x
Enterprise Value	11.8B 364M 326M 301M 273M 509M 34.69B 517M 3.6B 1.44B 18.17B 1.37B 1.34B 57.49B	EV / Sales 2024	26x	EV / Sales 2025	28.9x
Free-Float	48.64%	Yield 2024 *	-	Yield 2025	-

10-12	Foresee Pharmaceuticals Co., Ltd. and Changchun GeneScience Pharmaceutical Co., Ltd. Receive China NMPA Approval of CAMCEVI 42 Mg for Treatment of Advanced Prostate Cancer	CI
08-14	Foresee Pharmaceuticals Co., Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
07-09	Foresee Pharmaceuticals Co., Ltd. Announces Appointment of Brian J. Groch to Chief Commercial Officer, Effective July 1, 2026	CI
06-08	Foresee Pharmaceuticals Oral ALDH2 Activator Mirivadelgat Enters Clinical Testing in Parkinson's Disease in the SLEIPNIR Phase 2A Platform Trial	CI
05-27	Foresee Pharmaceuticals Completes Casppian Phase 3 Study and Confirms Topline Results for FP-001 42 Mg in Central Precocious Puberty	CI
05-13	Foresee Pharmaceuticals Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
03-13	Foresee Pharmaceuticals Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
03-06	Foresee Pharmaceuticals Announces Positive ChHMP Opinion Recommending Approval Of CAMCEVI 21 Mg 3-Month Strength In European Union	CI
02-04	Foresee Pharmaceuticals Co., Ltd. Receives the Fourth Positive Recommendation from the DSMB to Continue the Casppian Ph3 Study, for Central Precocious Puberty	CI
12-24	Foresee Pharmaceuticals Announces Casppian Phase 3 Study Meets Primary Efficacy Endpoint, Demonstrating Robust Lh Suppression with 6-Month Dosing Interval of Leuprolide Mesylate	CI
11-13	Foresee Pharmaceuticals Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
25-08-29	Foresee Pharmaceuticals Announces FDA Approval of CAMCEVI ETM for the Treatment of Advanced Prostate Cancer	CI
25-08-12	Foresee Pharmaceuticals Co., Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI

24-08-12	Foresee Pharmaceuticals Announces Several New Developments Related to its SIF Long-Acting Injectable (LAI) Technologies - Solidifying its Position as a Leader in Complex Long-Acting Injectable Products	AQ
24-04-02	Foresee Pharmaceuticals Receives Positive Recommendation from DSMB to Continue the Casppian Study, a Phase 3 Clinical Trial of Leuprolide Injectable Emulsion for the Treatment of CPP	AQ
23-10-31	Foresee Pharmaceuticals to Present at the American Heart Association Annual Meeting Focusing on its ALDH2 activator FP-045 in Pulmonary Hypertension Associated with Interstitial Lung Disease	AQ
23-10-02	Foresee Pharmaceuticals to Present Phase 1/2 Fanconi Anemia Clinical Study Design for its ALDH2 activator FP-045 at the Fanconi Anemia Research Fund 2023 Scientific Symposium	AQ
23-10-02	Foresee Pharmaceuticals Announces Publication of Preclinical Data in Nature Communications	AQ

Foresee Pharmaceuticals Co., Ltd. Stock

Stocks

6576

TW0006576002

Biotechnology & Medical Research

Valuation: Foresee Pharmaceuticals Co., Ltd.

Chart: Foresee Pharmaceuticals Co., Ltd.

Latest news: Foresee Pharmaceuticals Co., Ltd.

Press Releases: Foresee Pharmaceuticals Co., Ltd.

Quotes and Performance

Price Extremes

Managers and Directors: Foresee Pharmaceuticals Co., Ltd.

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Analysts' Consensus

Quarterly revenue - Rate of surprise

1 day	+1.73%
1 week	-0.78%
Current month	-3.77%
1 month	-4.61%
3 months	-6.25%
6 months	-6.13%
Current year	-5.09%

1 week	75.2	76.7
1 month	75.2	86
Current year	75.1	88.3
1 year	71.9	93.7
3 years	57.7	107.5
5 years	57.7	141
10 years	35.1	141

Manager	Title	Age	Since
Benjamin Chien CEO	Chief Executive Officer	-	2013-02-07
Yu Hua Li CTO	Chief Tech/Sci/R&D Officer	-	2015-07-08
Max Chan DFI	Director of Finance/CFO	58	2019-10-06

Director	Title	Age	Since
Chang Jen Yan BRD	Director/Board Member	-	2013-01-09
Sheng Lee Yi BRD	Director/Board Member	-	2013-01-09
George Lee BRD	Director/Board Member	75	2015-08-02

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
FORESEE PHARMACEUTICALS CO., LTD.	+1.73%	-0.78%	-2.55%	-8.82%	365M
WUXI APPTEC CO., LTD.	+0.65%	-3.56%	+33.53%	+60.50%	63.48B
ARGENX SE	+1.76%	+2.10%	+12.10%	+81.21%	54.55B
LONZA GROUP AG	-0.94%	+0.77%	+8.85%	+100.19%	53.59B
IQVIA HOLDINGS INC.	+2.76%	+4.18%	+28.34%	+55.07%	44.75B
BEONE MEDICINES AG	+2.00%	-2.90%	+18.37%	+119.04%	41.62B
REVOLUTION MEDICINES, INC.	+1.34%	-3.98%	+225.44%	+914.08%	39.91B
CELLTRION, INC.	+0.64%	-3.85%	+11.71%	+45.57%	32.47B
GENMAB A/S	+29.06%	+48.65%	+106.84%	+92.73%	26.7B
WUXI BIOLOGICS (CAYMAN) INC.	+3.72%	-7.45%	+24.25%	-2.99%	23.36B
Average	+4.27%	-0.45%	+46.69%	+145.66%	38.08B
Weighted average by Cap.	+3.23%	-0.29%	+47.51%	+161.31%

	2024	2025
Net sales	419M 12.92M 11.57M 10.68M 9.69M 18.05M 1.23B 18.33M 128M 50.93M 644M 48.48M 47.47M 2.04B	431M 13.31M 11.92M 11M 9.98M 18.6M 1.27B 18.88M 132M 52.46M 664M 49.94M 48.9M 2.1B
Net income	-1.08B -33.37M -29.88M -27.58M -25.01M -46.62M -3.18B -47.33M -330M -131M -1.66B -125M -123M -5.26B	-883M -27.26M -24.41M -22.53M -20.43M -38.08M -2.6B -38.67M -270M -107M -1.36B -102M -100M -4.3B
Net Debt	-1.11B -34.17M -30.59M -28.24M -25.61M -47.73M -3.25B -48.47M -338M -135M -1.7B -128M -126M -5.39B	-248M -7.65M -6.85M -6.32M -5.73M -10.68M -728M -10.85M -75.65M -30.14M -381M -28.69M -28.09M -1.21B